FDA has approved Pertuzumab [Perjeta] in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer
June 11, 2012 – The American Food and Drug Administration (FDA) has approved Pertuzumab [Perjeta]. Pertuzumab [Perjeta] is approved in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have …